Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
9.07
-0.03 (-0.28%)
Feb 19, 2026, 4:00 PM EST - Market closed
Prothena Corporation Employees
Prothena Corporation had 163 employees as of December 31, 2024. The number of employees decreased by 10 or -5.78% compared to the previous year.
Employees
163
Change (1Y)
-10
Growth (1Y)
-5.78%
Revenue / Employee
$72,307
Profits / Employee
-$1,720,607
Market Cap
487.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 163 | -10 | -5.78% |
| Dec 31, 2023 | 173 | 46 | 36.22% |
| Dec 31, 2022 | 127 | 45 | 54.88% |
| Dec 31, 2021 | 82 | 16 | 24.24% |
| Dec 31, 2020 | 66 | 15 | 29.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| Lyell Immunopharma | 300 |
| ADC Therapeutics | 265 |
| Allogene Therapeutics | 229 |
| 4D Molecular Therapeutics | 227 |
| Gossamer Bio | 145 |
| Invivyd | 100 |
| Ocugen | 95 |
PRTA News
- 7 days ago - Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire
- 2 months ago - Prothena Announces Board of Directors Update - Business Wire
- 3 months ago - Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - Business Wire
- 3 months ago - Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA - Business Wire
- 3 months ago - Prothena Reports Third Quarter 2025 Financial Results and Business Highlights - Business Wire
- 4 months ago - Prothena to Report Third Quarter 2025 Financial Results on November 6 - Business Wire
- 5 months ago - Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease - Business Wire
- 6 months ago - Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Business Wire